U.S. markets open in 4 hours 34 minutes
  • S&P Futures

    4,153.75
    -1.75 (-0.04%)
     
  • Dow Futures

    33,914.00
    -44.00 (-0.13%)
     
  • Nasdaq Futures

    13,906.50
    +9.25 (+0.07%)
     
  • Russell 2000 Futures

    2,222.40
    -6.90 (-0.31%)
     
  • Crude Oil

    64.09
    +0.71 (+1.12%)
     
  • Gold

    1,768.90
    -1.70 (-0.10%)
     
  • Silver

    25.91
    +0.07 (+0.26%)
     
  • EUR/USD

    1.2069
    +0.0028 (+0.23%)
     
  • 10-Yr Bond

    1.6010
    0.0000 (0.00%)
     
  • Vix

    17.63
    +1.38 (+8.49%)
     
  • GBP/USD

    1.3987
    +0.0003 (+0.02%)
     
  • USD/JPY

    108.4730
    +0.3230 (+0.30%)
     
  • BTC-USD

    55,224.66
    -2,197.42 (-3.83%)
     
  • CMC Crypto 200

    1,244.94
    -54.02 (-4.16%)
     
  • FTSE 100

    6,965.47
    -34.61 (-0.49%)
     
  • Nikkei 225

    29,100.38
    -584.99 (-1.97%)
     

Recap: Ultragenyx Pharmaceutical Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) rose in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share rose 77.16% over the past year to ($0.37), which beat the estimate of ($1.16).

Revenue of $91,542,000 higher by 157.19% year over year, which beat the estimate of $70,540,000.

Looking Ahead

Ultragenyx Pharmaceutical hasn't issued any earnings guidance for the time being.

Ultragenyx Pharmaceutical hasn't issued any revenue guidance for the time being.

How To Listen To The Conference Call

Date: Feb 11, 2021

View more earnings on RARE

Time: 05:00 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/gsc2oah6

Recent Stock Performance

Company's 52-week high was at $179.65

Company's 52-week low was at $31.99

Price action over last quarter: Up 71.35%

Company Description

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.